• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login/ Register
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: November 2021

Finance

Everimmune raises €5m to enter clinical phase in microbiome immuno-oncology

November 30, 2021 Microbiome Times

EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than €5 million (approx. $6M) in a Series A funding from […]

Editor's Choice

Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives

November 23, 2021 Aaron B Cowley and Nicole O'Brien

Live biotherapeutic products (LBPs) are defined by the U.S. FDA as biological products that contain live organisms applicable to the prevention, treatment, or cure of a disease or condition (1). LBP therapies continue to attract […]

Pharma & Human Health

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

November 19, 2021 Microbiome Times

Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, announced positive results from a Phase 1 study of orally-administered NOV-001 in healthy volunteers. The Phase 1 study demonstrated the ability […]

Biotech Showcase

Engineering the Microbiome to Treat Skin Diseases

November 16, 2021 Travis Whitfill

  The skin microbiome plays a fundamental role in human health, protecting against pathogens and antigens, while bolstering cutaneous immunity. Imbalances in the skin microbiome (i.e. “dysbiosis”) are highly associated with severity of skin disease, […]

Pharma & Human Health

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

November 12, 2021 Microbiome Times

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced positive topline results […]

Finance

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

November 10, 2021 Microbiome Times

SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate […]

Finance

ADM to Acquire Deerland Probiotics & Enzymes

November 5, 2021 Microbiome Times

ADM (NYSE: ADM), a global leader in nutrition and agricultural origination and processing, announced a significant expansion of its broad portfolio of health and wellness products and solutions with an agreement to purchase U.S.-based Deerland […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • “Probiotics” Green-lit for market-usage by French Authorities
    January 25, 2023
  • Microbiome Drug Development: 2022 in Review
    December 30, 2022
  • Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals
    December 22, 2022
  • FDA Approves First Fecal Microbiota Product
    December 1, 2022
  • Proge Farm claims Europe’s first regulatory approval for a microbiome-based therapeutic
    November 29, 2022
sign up

Sign up to the Microbiome Times newsletter